RETATRUTIDE

Retatrutide is a novel investigational peptide that functions as a triple agonist, targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This multi-receptor activity is designed to enhance metabolic regulation by improving insulin sensitivity, reducing appetite, increasing energy expenditure, and promoting weight reduction.

In research settings, Retatrutide has been studied for its ability to deliver greater efficacy in weight management and glycemic control compared to single- or dual-agonist therapies. By engaging three distinct pathways, Retatrutide may provide synergistic benefits for metabolic health, making it a key focus in obesity and type 2 diabetes research.

Potential applications of Retatrutide peptide research include:

✔ Weight management studies with superior reductions in body fat and appetite suppression

✔ Type 2 diabetes research focused on glycemic control and insulin sensitivity

✔ Metabolic health studies exploring energy expenditure and improved lipid profiles

✔ Cardiovascular risk reduction research through comprehensive metabolic regulation

Active Ingredient
Retatrutide

Other ingredients
Mannitol

Retatrutide - 14mg Vial

Retatrutide - 28mg Vial